Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.

Ekso Bionics Holdings, Inc.

Ekso Bionics EKSO recently announced a research partnership with Shepherd Center, a renowned rehabilitation hospital in Atlanta, to incorporate EksoNR and Ekso Indego devices across its rehabilitation and community network.
Shepherd Center is known to offer top-notch clinical care, research, and family support to patients with the most complicated illnesses, such as multiple sclerosis, traumatic amputations, spinal cord and brain injuries, stroke, and pain.
More on the Partnership
Ekso Bionics and Shepherd Center will collaborate to create a training and research program for the Ekso devices as part of their relationship. It is anticipated that the experience will enable the understanding of the best ways to incorporate Ekso device training into clinical programs and support individual Ekso Indego Personal device use.
Shepherd Center is set to work with Ekso Bionics to design a training program for the Ekso Indego Personal device, which Ekso Bionics expects will offer individuals the opportunity to experience and explore exoskeleton technology, empowering those interested in purchasing a home device with the knowledge and skills needed for successful integration into their daily lives.
With its expertise in spinal cord injury (SCI) and its programming, Shepherd Center is in a unique position to study the potential benefits of integrating exoskeleton technology into healthcare from the hospital to the patient's home.
More on Ekso Devices
EksoNR is a rehabilitation device that assists patients in standing and walking. It works with healthcare professionals to provide the required support to the patient's trunk and legs, encouraging appropriate movement patterns throughout the entire physical rehabilitation process. It also presents challenges to patients as they get closer to leaving the EksoNR rehabilitation facility and returning to their daily lives.
Ekso Indego Therapy gives medical professionals a means to offer patients who have had a stroke or spinal cord injury customized gait rehabilitation. A particular robotic-aided walking pattern can be taught using two different software packages, and assessments can be performed after the gait pattern has been eliminated. The easy-to-use iOS application allows for adjustments of numerous settings and viewing of analytics on patient and device performance can be used to improve treatment plans.
Ekso Indego Personal enables those with spinal cord injuries a new level of functional independence and upright mobility in their home and community. With its modular design of five interconnecting components and only weighing 29 lbs, Ekso Indego Personal is designed for ease of use and intuitive operation. It offers an easy set-up and a quick learning curve with most users standing and walking their first time in the device.
Industry Prospects
Per a report by Grand View Research, the global exoskeleton market size, which was valued at $419.5 million in 2023, is expected to witness a growth rate of 16.6% from 2024 to 2030.
Rapid technological advancements in theglobal marketare expected to boost the demand for exoskeletons. Increasing popularity and the growing adoption of exoskeletons by companies are expected to contribute to market growth. Furthermore, the increasing rate of incidence of SCI is expected to drive the demand across global markets.
Price Performance
For the past six months, EKSO’s shares have plunged 39.5% against the industry’s rise of 4.4%. The S&P 500 increased 14.3% in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Other Stocks to Consider
EKSO carries a Zacks Rank #2 (Buy) at present.
Some other top-ranked stocks in the broader medical space that have announced quarterly results are DaVita DVA, Ecolab ECL and Universal Health Services UHS.
DaVita, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DaVita’s shares have gained 44% compared with the industry’s 20.4% rise in the past year.
Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.7%.
Ecolab’s shares have rallied 33.8% against the industry’s 9.3% decline in the past year.
Universal Health Services has an Earnings ESP of +2.91% and a Zacks Rank #2 at present. UHS has an estimated earnings growth rate of 30.5% for 2024.
UHS’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.12%.
Buy 5 Stocks BEFORE Election Day
Biden or Trump? Zacks is releasing a FREE Special Report, Profit from the 2024 Presidential Election (no matter who wins).
Since 1950, presidential election years have been strong for the market. This report names 5 timely stocks to ride the wave of electoral excitement.
They include a medical manufacturer that gained +11,000% in the last 15 years… a rental company absolutely crushing its sector… an energy powerhouse planning to grow its already large dividend by 25%... an aerospace and defense standout that just landed a potentially $80 billion contract… and a giant chipmaker building huge plants in the U.S.
Don’t Wait. Download FREE >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ecolab Inc. (ECL) : Free Stock Analysis Report
Universal Health Services, Inc. (UHS) : Free Stock Analysis Report
DaVita Inc. (DVA) : Free Stock Analysis Report
Ekso Bionics Holdings, Inc. (EKSO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Ekso Bionics' (EKSO) New Partnership to Aid Its Ekso Devices

The following companies are expected to report earnings after hours on 03/04/2024. Visit our Earnings Calendar for a full list of expected earnings releases.
GitLab Inc. (GTLB)is reporting for the quarter ending January 31, 2024. The consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.19. GTLB reported earnings of $-0.26 per share for the same quarter a year ago; representing a a decrease of -26.92%.AeroVironment, Inc. (AVAV)is reporting for the quarter ending January 31, 2024. The consensus earnings per share forecast from the 3 analysts that follow the stock is $0.32. AVAV reported earnings of $0.33 per share for the same quarter a year ago; representing a a decrease of -3.03%.Northwest Pipe Company (NWPX)is reporting for the quarter ending December 31, 2023. The consensus earnings per share forecast from the 3 analysts that follow the stock is $0.42. NWPX reported earnings of $0.85 per share for the same quarter a year ago; representing a a decrease of -50.59%.The days to cover, as reported in the 2/15/2024 short interest update, increased 183.87% from previous report on 1/31/2024. Stitch Fix, Inc. (SFIX)is reporting for the quarter ending January 31, 2024. The consensus earnings per share forecast from the 8 analysts that follow the stock is $-0.21. SFIX reported earnings of $-0.34 per share for the same quarter a year ago; representing a a decrease of -38.24%.Akoya BioSciences, Inc. (AKYA)is reporting for the quarter ending December 31, 2023. The consensus earnings per share forecast from the 4 analysts that follow the stock is $-0.27. AKYA reported earnings of $-0.5 per share for the same quarter a year ago; representing a a decrease of -46.00%.ThredUp Inc. (TDUP)is reporting for the quarter ending December 31, 2023. The consensus earnings per share forecast from the 5 analysts that follow the stock is $-0.13. TDUP reported earnings of $-0.19 per share for the same quarter a year ago; representing a a decrease of -31.58%. The "days to cover" for this stock exceeds 13 days.Eos Energy Enterprises, Inc. (EOSE)is reporting for the quarter ending December 31, 2023. The consensus earnings per share forecast from the 5 analysts that follow the stock is $-0.22. EOSE reported earnings of $-0.68 per share for the same quarter a year ago; representing a a decrease of -67.65%.Nektar Therapeutics (NKTR)is reporting for the quarter ending December 31, 2023. The consensus earnings per share forecast from the 4 analysts that follow the stock is $-0.20. NKTR reported earnings of $-0.32 per share for the same quarter a year ago; representing a a decrease of -37.50%.Viant Technology Inc. (DSP)is reporting for the quarter ending December 31, 2023. The consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.20. DSP reported earnings of $-0.15 per share for the same quarter a year ago; representing a a increase of 33.33%.Cara Therapeutics, Inc. (CARA)is reporting for the quarter ending December 31, 2023. The consensus earnings per share forecast from the 3 analysts that follow the stock is $-0.57. CARA reported earnings of $-0.56 per share for the same quarter a year ago; representing a a increase of 1.79%.Ekso Bionics Holdings, Inc. (EKSO)is reporting for the quarter ending December 31, 2023. The consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.11. EKSO reported earnings of $-0.24 per share for the same quarter a year ago; representing a a decrease of -54.17%.Grupo Aval Acciones y Valores S.A. (AVAL)is reporting for the quarter ending December 31, 2023. The consensus earnings per share forecast from the 2 analysts that follow the stock is $0.05. AVAL reported earnings of $0.1 per share for the same quarter a year ago; representing a a decrease of -50.00%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	0.00 23.75
Price/Sales	0.74 3.01
P/B	1.14 2.20
P/FCF	0.00 18.30

Indicator	TTM Median
Net Worth	0.02 0.20
Quick Ratio	2.14 1.71
Current Ratio	2.81 2.83

Indicator	TTM Median
Net Profit Margin	-55.56 10.25
Operating Margin	-61.11 14.24
Gross Margin	50.00 68.57

Indicator	TTM Median
EPS	0.10 0.37
EPS Forecast	0.08 0.37
Revenue	4.00M 16.00M
Gross Profit	2.00M —
EBITDA	-2.00M —

Ekso Bionics Holdings, Inc.

Indicators EKSO

Valuation

Debts

Efficiency

Other ratios

Revenue